KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Pharmaceuticals, Inc. (OTCBB: PVCT, http://www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company, has held its third end-of-Phase 2 meeting with the U.S. Food and Drug Administration (“FDA”). The meeting, held October 18, 2011, addressed several topics central to definition of the applicable patient population and primary endpoint for the Company’s planned pivotal Phase 3 randomized controlled trial (“RCT”) of PV-10 for metastatic melanoma. Provectus is seeking consensus on design of the study that qualifies for Special Protocol Assessment (“SPA”) and supports approval of PV-10 for its melanoma indication.
